Oruka Therapeutics, Inc. (ORKA) shareholders
Close on Nov 17, 2026Market cap $6.38BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Harwin Peter Evan Joint filing with Fairmount Funds Management LLC (19.47%), Kiselak Tomas (19.47%) and 1 more | 14,572,917 | 19.50% | 13D (active) amendment | Jul 1, 2026 |
| Fairmount Funds Management LLC Joint filing with Kiselak Tomas (19.99%), Harwin Peter Evan (19.99%) and 1 more | 13,665,080 | 19.99% | 13D (active) amendment | Apr 30, 2026 |
| Tomas Kiselak Joint filing with Fairmount Funds Management LLC (19.99%), Peter Evan Harwin (19.99%) and 2 more | 11,162,741 | 19.99% | 13D (active) amendment | Sep 17, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (15.35%) | 5,512,300 | 15.35% | 13G (passive) | Oct 7, 2024 |
| Bong Y. Koh Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 4,909,619 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Venrock Healthcare Capital Partners III, L.P. Joint filing with VHCP Co-Investment Holdings III, LLC (7.40%), Venrock Healthcare Capital Partners EG, L.P. (7.40%) and 4 more | 4,556,952 | 7.40% | 13G (passive) amendment | Jun 30, 2026 |
| Bong Y Koh Joint filing with Venrock Healthcare Capital Partners III, L.P. (11.10%), VHCP Co-Investment Holdings III, LLC (11.10%) and 4 more | 4,148,428 | 11.10% | 13G (passive) amendment | Feb 10, 2025 |
| Capital World Investors | 3,401,639 | 5.60% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 3,175,483 | 6.60% | 13G (passive) | Dec 31, 2025 |
| Roderick Wong Joint filing with RTW Investments, LP (5.20%) | 3,139,030 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Viking Global Investors LP Joint filing with Viking Global Opportunities Parent GP LLC (5.30%), Halvorsen Ole Andreas (5.30%) and 1 more | 2,666,690 | 5.30% | 13G (passive) amendment | Mar 31, 2026 |
| Shabet Rose Sharon Joint filing with Viking Global Investors LP (5.50%), Viking Global Opportunities Parent GP LLC (5.50%) and 2 more | 2,666,690 | 5.50% | 13G (passive) | Sep 17, 2025 |
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (5.20%) | 1,945,649 | 5.20% | 13G (passive) | Mar 31, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (5.07%), David Kroin (5.07%) | 1,896,780 | 5.07% | 13G (passive) | May 6, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ORKA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,057,645 | 13.68% | $862.02M | +1,626,242 | 0.04% |
| BlackRock, Inc. | 4,990,181 | 7.54% | $474.92M | +1,463,094 | 0.01% |
| VR Adviser, LLC | 4,148,428 | 6.27% | $394.81M | – | 11.97% |
| Fairmount Funds Management LLC | 3,705,262 | 5.60% | $352.63M | – | 23.31% |
| Capital World Investors | 3,401,639 | 5.14% | $323.73M | New | 0.04% |
| Rtw Investments, LP | 3,139,030 | 4.74% | $298.74M | +1,080,882 | 2.55% |
| State Street Corp | 2,673,090 | 4.04% | $254.38M | +1,059,629 | 0.01% |
| Vanguard Capital Management LLC | 2,360,971 | 3.57% | $224.69M | +501,340 | 0.00% |
| Paradigm Biocapital Advisors LP | 2,144,526 | 3.24% | $204.09M | −175,790 | 3.82% |
| Deep Track Capital, LP | 1,926,000 | 2.91% | $183.30M | −108,203 | 2.67% |
| Bellevue Group AG | 1,657,190 | 2.50% | $157.71M | +1,150,182 | 3.32% |
| Franklin Resources Inc | 1,621,451 | 2.45% | $154.31M | +617,395 | 0.03% |
| Remedium Capital Partners, LLC | 1,565,661 | 2.36% | $149.00M | – | 32.99% |
| Ra Capital Management, L.P. | 1,554,597 | 2.35% | $147.95M | New | 1.29% |
| Viking Global Investors LP | 1,503,478 | 2.27% | $143.09M | −1,163,212 | 0.41% |
| Geode Capital Management, LLC | 1,429,954 | 2.16% | $136.11M | +475,087 | 0.01% |
| Jupiter Topco LLC | 1,375,844 | 2.08% | $130.97M | New | 0.05% |
| Perceptive Advisors LLC | 1,345,063 | 2.03% | $128.01M | −50,438 | 1.92% |
| Polar Capital Holdings Plc | 1,228,609 | 1.86% | $116.93M | +180,916 | 0.28% |
| Citadel Advisors LLC | 1,119,011 | 1.69% | $106.50M | +111,474 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 256 | 74M | 100.0% | 101 / 94 | 47 / 27 | 27M | 6M |
| Q1 2026 | 184 | 53M | 79.9% | 63 / 65 | 31 / 20 | 9M | 6M |
| Q4 2025 | 143 | 53M | 79.8% | 46 / 53 | 17 / 8 | 10M | 3M |
| Q3 2025 | 105 | 46M | 68.8% | 32 / 32 | 21 / 8 | 13M | 2M |
| Q2 2025 | 81 | 34M | 52.0% | 25 / 27 | 14 / 15 | 5M | 2M |
| Q1 2025 | 71 | 32M | 48.0% | 16 / 28 | 12 / 10 | 5M | 4M |
| Q4 2024 | 66 | 31M | 46.9% | 29 / 20 | 8 / 5 | 9M | 2M |
| Q3 2024 | 42 | 25M | 37.1% | 42 / 0 | 0 / 0 | 25M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
259 funds held ORKA in Q2 2026, 32% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ORKA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,724,692 | 2.60% | $164.14M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,555,002 | 2.35% | $147.99M | 1.38% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,527,592 | 2.31% | $145.38M | 0.15% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,300,202 | 1.96% | $123.74M | 0.15% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,221,046 | 1.84% | $71.47M | 0.07% | May 31, 2026 |
| Select Health Care Portfolio | 833,100 | 1.26% | $48.76M | 0.84% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 737,386 | 1.11% | $71.17M | 3.24% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 685,718 | 1.04% | $66.18M | 0.75% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 580,953 | 0.88% | $55.29M | 0.06% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 562,683 | 0.85% | $32.93M | 0.63% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 550,743 | 0.83% | $53.15M | 0.16% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 451,118 | 0.68% | $42.93M | 0.36% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 449,195 | 0.68% | $42.75M | 0.28% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 428,000 | 0.65% | $41.31M | 1.32% | Jul 31, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 381,128 | 0.58% | $36.27M | 0.39% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lawrence Otto Klein | Chief Executive Officer, Director | 923,128 | 1.39% | Nov 2, 2026 |
| Joana Goncalves | Chief Medical Officer | 31,771 | 0.05% | Nov 16, 2026 |
| Arjun Agarwal | Senior Vice President, Finance | 14,219 | 0.02% | Nov 13, 2026 |
| Paul T. Quinlan | General Counsel | 29,995 | 0.05% | Oct 20, 2026 |
| Laura Lee Sandler | Chief Operating Officer | 235,478 | 0.36% | Sep 15, 2026 |
| Larry Todd Edwards | Chief Commercial Officer | 100,000 | 0.15% | Aug 25, 2026 |
| Kristine M. Ball | Director | 0 | – | Nov 13, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Jul 1, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | – | – | Jul 1, 2026 |
| Tomas Kiselak | Director, 10% owner | 7,258,672 | 10.96% | Jul 1, 2026 |
| Healthcare Co-Invest III L.P. Fairmount | Director, 10% owner | – | – | Jul 1, 2026 |
| Peter Evan Harwin | Director, 10% owner | 2,936,922 | 4.44% | Jul 1, 2026 |
| Carl Dambkowski | Director | 38,743 | 0.06% | Jun 12, 2026 |
| Christopher Nathan Martin | Director | – | – | Jun 3, 2026 |
| Samarth Kulkarni | Director | – | – | Jun 3, 2026 |
| Cameron Turtle | Director | 85,233 | 0.13% | Jun 3, 2025 |
| VHCP Management III, LLC | 10% owner | 4,025,546 | 6.08% | Feb 27, 2025 |
| VHCP Co-Investment Holdings III, LLC | 10% owner | – | – | Feb 27, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 10% owner | – | – | Feb 27, 2025 |
| VHCP Management EG, LLC | 10% owner | – | – | Feb 27, 2025 |
| Venrock Healthcare Capital Partners EG, L.P. | 10% owner | – | – | Feb 27, 2025 |
| Nimish P. Shah | 10% owner | – | – | Feb 27, 2025 |
| Bong Y. Koh | 10% owner | 0 | – | Feb 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −500 | $105.86 | $52.93K | 31,771 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −200 | $103.36 | $20.67K | 32,271 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −300 | $102.47 | $30.74K | 32,471 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −1,900 | $101.53 | $192.90K | 32,771 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −1,500 | $100.48 | $150.72K | 34,671 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −2,600 | $99.52 | $258.74K | 36,171 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 38,771 |
| Joana Goncalves Chief Medical Officer | Nov 16, 2026 | Option exercise | +3,500 | $6.84 | $23.94K | 35,271 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Sale(10b5-1 plan) | −100 | $107.00 | $10.70K | 14,219 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Sale(10b5-1 plan) | −958 | $106.18 | $101.72K | 14,319 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Sale(10b5-1 plan) | −6,842 | $105.28 | $720.33K | 15,277 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Sale(10b5-1 plan) | −799 | $104.25 | $83.30K | 22,119 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Sale(10b5-1 plan) | −801 | $103.16 | $82.63K | 22,918 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Sale(10b5-1 plan) | −500 | $101.98 | $50.99K | 23,719 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Option exercise | +1,458 | $34.39 | $50.14K | 24,219 |
| Arjun Agarwal Senior Vice President, Finance | Nov 12, 2026 | Option exercise | +8,542 | $12.50 | $106.78K | 22,761 |
| Kristine M. Ball Director | Nov 12, 2026 | Sale(10b5-1 plan) | −200 | $106.98 | $21.40K | 0 |
| Kristine M. Ball Director | Nov 12, 2026 | Sale(10b5-1 plan) | −2,500 | $106.05 | $265.13K | 200 |
| Kristine M. Ball Director | Nov 12, 2026 | Sale(10b5-1 plan) | −10,765 | $105.31 | $1.13M | 2,700 |
| Kristine M. Ball Director | Nov 12, 2026 | Sale(10b5-1 plan) | −2,039 | $104.16 | $212.39K | 13,465 |
| Kristine M. Ball Director | Nov 12, 2026 | Sale(10b5-1 plan) | −1,300 | $103.09 | $134.02K | 15,504 |
| Kristine M. Ball Director | Nov 12, 2026 | Sale(10b5-1 plan) | −1,196 | $102.10 | $122.11K | 16,804 |
| Kristine M. Ball Director | Nov 12, 2026 | Option exercise | +18,000 | $6.84 | $123.12K | 18,000 |
| Lawrence Otto Klein Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −300 | $98.40 | $29.52K | 923,128 |
| Lawrence Otto Klein Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −756 | $97.45 | $73.68K | 923,428 |
| Lawrence Otto Klein Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −2,442 | $96.70 | $236.15K | 924,184 |
| Lawrence Otto Klein Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −15,036 | $95.64 | $1.44M | 926,626 |
| Lawrence Otto Klein Chief Executive Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −6,466 | $94.77 | $612.79K | 941,662 |
| Lawrence Otto Klein Chief Executive Officer, Director | Nov 2, 2026 | Option exercise | +25,000 | $7.80 | $195.00K | 948,128 |
| Paul T. Quinlan General Counsel | Oct 20, 2026 | Sale(10b5-1 plan) | −3,000 | $79.49 | $238.47K | 29,995 |
| Paul T. Quinlan General Counsel | Oct 20, 2026 | Sale(10b5-1 plan) | −4,100 | $78.79 | $323.04K | 32,995 |
| Paul T. Quinlan General Counsel | Oct 20, 2026 | Sale(10b5-1 plan) | −1,000 | $77.20 | $77.21K | 37,095 |
| Paul T. Quinlan General Counsel | Oct 20, 2026 | Sale(10b5-1 plan) | −500 | $76.12 | $38.06K | 38,095 |
| Paul T. Quinlan General Counsel | Oct 20, 2026 | Sale(10b5-1 plan) | −400 | $74.90 | $29.96K | 38,595 |
| Paul T. Quinlan General Counsel | Oct 20, 2026 | Option exercise | +9,000 | $7.80 | $70.20K | 38,995 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Sale(10b5-1 plan) | −200 | $77.71 | $15.54K | 31,771 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Sale(10b5-1 plan) | −700 | $76.67 | $53.67K | 31,971 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Sale(10b5-1 plan) | −1,400 | $75.48 | $105.68K | 32,671 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Sale(10b5-1 plan) | −1,847 | $74.69 | $137.96K | 34,071 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Sale(10b5-1 plan) | −2,853 | $73.89 | $210.81K | 35,918 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 38,771 |
| Joana Goncalves Chief Medical Officer | Oct 15, 2026 | Option exercise | +3,500 | $6.84 | $23.94K | 35,271 |
| Arjun Agarwal Senior Vice President, Finance | Oct 12, 2026 | Sale(10b5-1 plan) | −200 | $82.83 | $16.57K | 14,219 |
| Arjun Agarwal Senior Vice President, Finance | Oct 12, 2026 | Sale(10b5-1 plan) | −1,958 | $81.86 | $160.27K | 14,419 |
| Arjun Agarwal Senior Vice President, Finance | Oct 12, 2026 | Sale(10b5-1 plan) | −2,100 | $80.76 | $169.60K | 16,377 |
| Arjun Agarwal Senior Vice President, Finance | Oct 12, 2026 | Sale(10b5-1 plan) | −5,741 | $80.03 | $459.45K | 18,477 |
| Arjun Agarwal Senior Vice President, Finance | Oct 12, 2026 | Option exercise | +1,458 | $34.39 | $50.14K | 24,218 |
| Arjun Agarwal Senior Vice President, Finance | Oct 12, 2026 | Option exercise | +8,541 | $12.50 | $106.76K | 22,760 |
| Lawrence Otto Klein Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −200 | $84.78 | $16.96K | 923,128 |
| Lawrence Otto Klein Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −8,554 | $84.03 | $718.75K | 923,328 |
| Lawrence Otto Klein Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −16,246 | $83.40 | $1.35M | 931,882 |
| Lawrence Otto Klein Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +25,000 | $7.80 | $195.00K | 948,128 |
| Paul T. Quinlan General Counsel | Sep 21, 2026 | Sale(10b5-1 plan) | −3,832 | $93.32 | $357.60K | 33,263 |
| Paul T. Quinlan General Counsel | Sep 21, 2026 | Sale(10b5-1 plan) | −601 | $94.44 | $56.76K | 32,662 |
| Paul T. Quinlan General Counsel | Sep 21, 2026 | Sale(10b5-1 plan) | −2,667 | $95.31 | $254.19K | 29,995 |
| Paul T. Quinlan General Counsel | Sep 21, 2026 | Sale(10b5-1 plan) | −2,900 | $92.37 | $267.87K | 37,095 |
| Paul T. Quinlan General Counsel | Sep 21, 2026 | Option exercise | +10,000 | $7.80 | $78.00K | 39,995 |
| Arjun Agarwal Senior Vice President, Finance | Sep 21, 2026 | Sale(10b5-1 plan) | −533 | $95.75 | $51.03K | 14,219 |
| Laura Lee Sandler Chief Operating Officer | Sep 15, 2026 | Sale | −906 | $95.71 | $86.71K | 235,478 |
| Paul T. Quinlan General Counsel | Sep 15, 2026 | Sale | −1,039 | $95.71 | $99.44K | 29,995 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oruka Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 138,421 shares on Sep 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lawrence Otto Klein Director, Officer | Nov 2, 2026 | 25,000 | $2.42M | Nov 2, 2026 | Exercise of Stock Options |
| Joana Goncalves Officer | Oct 15, 2026 | 21,000 | $1.61M | Oct 15, 2026 | Exercise of Stock Options |
| Arjun Agarwal Officer | Oct 13, 2026 | 9,999 | $821.02K | Oct 12, 2026 | Exercise of Stock Options |
| Lawrence Otto Klein Director, Officer | Oct 1, 2026 | 25,000 | $2.08M | Oct 1, 2026 | Exercise of Stock Options |
| Arjun Agarwal Officer | Sep 21, 2026 | 533 | $50.61K | Sep 21, 2026 | Restricted Stock Units |
| Lawrence Otto Klein Director, Officer | Sep 1, 2026 | 75,000 | $6.95M | Sep 1, 2026 | Exercise of Stock Options |
| Laura Lee Sandler Officer | Sep 1, 2026 | 5,000 | $463.10K | Sep 1, 2026 | Exercise of Stock Options |
| Paul T. Quinlan Officer | Aug 14, 2026 | 71,000 | $7.68M | Aug 14, 2026 | Exercise of Stock Options |
| Joana Goncalves Officer | Jul 15, 2026 | 21,000 | $1.84M | Jul 15, 2026 | Exercise of Stock Options |
| Arjun Agarwal Officer | Jul 13, 2026 | 28,588 | $2.48M | Jul 13, 2026 | Exercise of Stock Options |
| Healthcare Fund II L.P. Fairmount Director, 10% Stockholder | Jul 1, 2026 | 3,553,410 | $300.01M | Jul 1, 2026 | Conversion of Series B Non-Voting Convertible Preferred Stock |
| Carl Dambkowski Director | Jun 11, 2026 | 35,000 | $2.24M | Jun 11, 2026 | Partnership Distribution |
| Carl Dambkowski Director | May 21, 2026 | 105,000 | $6.37M | May 21, 2026 | Exercise of Stock Options |
| Arjun Agarwal Officer | May 18, 2026 | 22,206 | $1.38M | May 18, 2026 | Exercise of Stock Options |
| Laura Lee Sandler Officer | May 1, 2026 | 10,000 | $684.10K | May 1, 2026 | Exercise of Stock Options |
See a number that looks wrong?